ライフサイエンスコーパス: polyarticular

1 and pattern of arthritis (oligoarticular vs polyarticular).

2 s 4-18 years with JRA (17 pauciarticular, 23 polyarticular, 8 systemic) were compared with age-matche

3 from 119 JRA patients (72 pauciarticular, 47 polyarticular) and 111 healthy controls from Latvia was

4 type (6 sets with pauciarticular, 1 set with polyarticular), and disease onset was separated by a mea

5 ene transfer could be used to treat systemic polyarticular arthritides.

6 For a 2-month period, 51 children with polyarticular arthritis (mean age 12.4 years, 65% female

7 ndings for oligoarticular JIA, patients with polyarticular arthritis had no evidence of an HLA class

8 ronic inflammatory syndrome characterized by polyarticular arthritis, dermatitis, myeloid hyperplasia

9 ria and associated night sweats, fevers, and polyarticular arthritis.

10 s of daily disease symptoms in children with polyarticular arthritis.

11 eating the disease symptoms of children with polyarticular arthritis.

12 dditive effect with DRB1*JIASE in those with polyarticular, but not those with persistent oligoarticu

13 hdrawal phase 3 trial enrolled patients with polyarticular course JIA (extended oligoarthritis, rheum

14 In part 2, 142 patients with polyarticular course JIA were assigned to tofacitinib (n

15 25 patients enrolled, 184 (82%) patients had polyarticular course JIA, 20 (9%) had psoriatic arthriti

16 b is an effective treatment in patients with polyarticular course JIA.

17 e rate by week 44 in part 2 in patients with polyarticular course JIA; the intention-to-treat princip

18 tofacitinib versus placebo in patients with polyarticular course juvenile idiopathic arthritis (JIA)

19 A are associated with polyarticular onset, a polyarticular course, and erosive disease.

20 c-onset juvenile rheumatoid arthritis with a polyarticular course, in whom type 1 diabetes mellitus d

21 was true for both the pauciarticular and the polyarticular course.

22 ce liquid chromatography in 86 patients with polyarticular-course JIA (>/=5 joints affected) and 15 c

23 Initially, 159 patients with polyarticular-course JIA and 263 controls were studied,

24 of a replication cohort of 181 patients with polyarticular-course JIA and 355 controls.

25 Available parents of patients with polyarticular-course JIA were also genotyped.

26 be useful for research and clinical care in polyarticular-course JIA.

27 SP3*84A allele was observed in patients with polyarticular-course JIA.

28 WISP3 gene have been shown in patients with polyarticular-course JIA.

29 and replicated in 2 cohorts of patients with polyarticular-course JIA.

30 n acceptable safety profile in children with polyarticular-course JRA and provides significant improv

31 Patients with active polyarticular-course JRA who participated in an efficacy

32 d that etanercept treatment in patients with polyarticular-course juvenile rheumatoid arthritis (JRA)

33 noclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis.

34 Progression to polyarticular disease (>or=5 joints) is more common in y

35 rheumatoid factor-negative JRA patients with polyarticular disease and 2 JRA patients with pauciartic

36 nset of disease, and presence of systemic or polyarticular disease are all risk factors for temporoma

37 ticular onset (OR 7.46, 95% CI 1.99-28.0), a polyarticular disease course (OR 9.78, 95% CI 1.25-76.7)

38 Progression of pauciarticular to polyarticular disease occurred in 11% of the cases.

39 ticular-onset JRA; 19% were concordant for a polyarticular disease onset.

40 similar for children with oligoarticular and polyarticular disease, differences in bone mass were gre

41 For early-onset polyarticular disease, evidence of linkage was found at

42 expansions were found only in patients with polyarticular disease.

43 s in bone mass were greater in children with polyarticular disease.

44 We conducted deep WGS on children with the polyarticular form of juvenile idiopathic arthritis (JIA

45 Arthritis was polyarticular in 96% of patients.

46 There was clear evidence of polyarticular involvement in the hand joints of both the

47 f oligoarticular JIA (n = 62) as compared to polyarticular JIA (n = 36).

48 ) or from patients with early- or late-onset polyarticular JIA (with 89% accuracy), but not from pati

49 hritis (JIA), IgM rheumatoid factor-negative polyarticular JIA and oligoarticular JIA.

50 es were significantly lower in patients with polyarticular JIA and those with SpA.

51 hil abnormalities persisted in children with polyarticular JIA even after disease remission was achie

52 be sets distinguished 3 subgroups within the polyarticular JIA group.

53 sease activity and supported the division of polyarticular JIA into distinct subsets.

54 onducted in 85 children ages 2-16 years with polyarticular JIA of <12 months' duration.

55 s that were differentially expressed between polyarticular JIA patients and healthy controls.

56 milarities to early-onset oligoarticular and polyarticular JIA patients, including female preponderan

57 rom 59 healthy children and 61 children with polyarticular JIA prior to treatment with second-line me

58 res in PBMCs from patients with recent-onset polyarticular JIA reflect discrete disease processes and

59 in this cohort of children with recent-onset polyarticular JIA resulted in clinical inactive disease

60 Furthermore, patients with polyarticular JIA showed age-specific related effects, w

61 Neutrophil gene profiling in polyarticular JIA suggests important roles for neutrophi

62 For children with polyarticular JIA treated for 12 months with biologic ag

63 n all 4 measures; and children (n = 31) with polyarticular JIA treated with biologic agents for 12 mo

64 This is also true for patients with polyarticular JIA treated with biologic agents for 12 mo

65 ligoarticular and rheumatoid factor-negative polyarticular JIA), and 13,056 controls.

66 female; 24 with oligoarticular JIA, 40 with polyarticular JIA, 18 with systemic JIA, and 19 with spo

67 ular JIA, 45 with rheumatoid factor-negative polyarticular JIA, and 20 with systemic JIA).

68 mic JIA profile with data from patients with polyarticular JIA, chronic infantile neurologic, cutaneo

69 ained from children with oligoarticular JIA, polyarticular JIA, or systemic JIA were compared.

70 es were significantly lower in patients with polyarticular JIA, those with systemic JIA, and those wi

71 r JIA and the group of younger patients with polyarticular JIA.

72 ts with oligoarticular JIA and patients with polyarticular JIA.

73 JIA and a younger subgroup of patients with polyarticular JIA.

74 STAT4 variant was associated primarily with polyarticular JIA.

75 analysis to elucidate pathologic pathways in polyarticular JIA.

76 profiling on neutrophils from children with polyarticular JIA.

77 udy establishes evidence for linkage between polyarticular JRA and the HLA-DR region.

78 severe, longstanding, methotrexate-resistant polyarticular JRA demonstrated sustained clinical improv

79 are associated with HLA-DR4 in children with polyarticular JRA, whether anti-CCP antibodies are assoc

80 es of 10.2 and 10.7 years, respectively, for polyarticular JRA.

81 r, less mineralized skeleton was observed in polyarticular JRA.

82 For a 2-month period, 41 children with polyarticular juvenile arthritis completed daily diaries

83 biomarkers to predict response to therapy in polyarticular juvenile idiopathic arthritis (JIA) is an

84 ct in neutrophil activation in children with polyarticular juvenile idiopathic arthritis (JIA).

85 enrolled patients (aged 2 to <18 years) with polyarticular juvenile idiopathic arthritis (positive or

86 results of a pivotal trial of infliximab in polyarticular juvenile idiopathic arthritis suggested ef

87 cceptable safety profile in the treatment of polyarticular juvenile idiopathic arthritis, extended ol

88 ially girls, with rheumatoid factor positive polyarticular juvenile idiopathic arthritis, have the gr

89 Vbeta20 TCRs were selected as prototypic for polyarticular juvenile rheumatoid arthritis (JRA) and pa

90 as markedly increased over the prevalence of polyarticular juvenile rheumatoid arthritis (JRA) in the

91 or (p75):Fc fusion protein, in children with polyarticular juvenile rheumatoid arthritis who did not

92 nificant improvement in patients with active polyarticular juvenile rheumatoid arthritis.

93 lished report of simultaneous vasculitic and polyarticular manifestations in a patient with carcinoma

94 inistration was intramuscular if disease was polyarticular (n = 53) or intraarticular if patients had

95 joints, for OA at 2 or 3 hand sites, and for polyarticular OA (r = 0.33-0.81) when OA was defined acc

96 Polyarticular OA was recorded if there were OA findings

97 Anti-CCP antibodies were associated with polyarticular onset (OR 7.46, 95% CI 1.99-28.0), a polya

98 ti-CCP antibodies in JRA are associated with polyarticular onset, a polyarticular course, and erosive

99 This was true for both pauciarticular and polyarticular onset.

100 rom 230 HLA-typed patients with JRA (77 with polyarticular-onset disease and 153 with pauciarticular-

101 Among subjects with polyarticular-onset disease, significantly more joints w

102 cted joints at JRA onset among patients with polyarticular-onset disease.

103 lls from 20 patients with oligoarticular- or polyarticular-onset JIA.

104 Thirteen percent of the patients with polyarticular-onset JRA and 2% of the other JRA patients

105 y-seven percent of RF-positive patients with polyarticular-onset JRA had anti-CCP antibodies.

106 tial proportion of RF-positive patients with polyarticular-onset JRA have these antibodies.

107 HLA-DR4-positive patients with polyarticular-onset JRA were more likely to have anti-CC

108 cases had pauciarticular-onset JRA, 16% had polyarticular-onset JRA, and 11% had systemic-onset JRA.

109 en among those with pauciarticular-onset and polyarticular-onset JRA.

110 formation in HLA-DR4-positive patients with polyarticular-onset JRA.

111 f patients had pauciarticular-onset, 17% had polyarticular-onset, and 11% had systemic-onset disease.

112 ce (P < or = 0.04) and more frequently had a polyarticular or systemic disease course (P = 0.04) comp

113 nonrandomized registry of 594 patients with polyarticular or systemic JIA treated with etanercept on

114 ial fluid from children with oligoarticular, polyarticular, or systemic-onset JRA were assayed for FS

115 ) of disease in the JRA, pauciarticular, and polyarticular patient groups, respectively.

116 JIA, and 4.1 (95% CI 2.5-6.7) in those with polyarticular RF-negative JIA.

117 l most of the inflammatory features of early polyarticular rheumatoid arthritis (Table 2).

118 situations (e.g., active early inflammatory polyarticular rheumatoid arthritis) and in low doses, fr

119 patients with persistent oligoarticular and polyarticular rheumatoid factor (RF)-negative juvenile i

120 Adolescent girls with polyarticular rheumatoid factor-positive subtype appear

121 arthritis (JRA), particularly in those with polyarticular, rheumatoid factor (RF)-positive JRA.

122 This study confirms the existence of a polyarticular subset of OA among men that has characteri

123 ticular delivery of the vIL-10 gene may have polyarticular therapeutic effects.